Renal Cell Carcinoma

Pharmacor -- June 2008

  Introduction:

The recent launches of targeted therapies have revolutionized the treatment of renal cell carcinoma (RCC) and dramatically changed the market. However, the prognosis for patients with metastatic RCC remains very poor, and unmet need remains high in this indication.

  Questions Answered in This Report:

Sunitinib (Pfizer’s Sutent) is the first-line therapy of choice in patients with metastatic RCC. How will this practice change over the next five to ten years? Will any of the emerging targeted therapies challenge sunitinib’s position as the market leader?

No agents have yet proved effective in the adjuvant setting in patients with nonmetastatic RCC. Will the recently launched targeted therapies prove effective in this setting? Will any new emerging therapies launch for the treatment of this patient segment?

Several cancer vaccines are in development for RCC. What do thought-leading physicians think about their prospects for RCC? Which cancer vaccines are the most promising, and which patient segments are they targeting?

  Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 22 country-specific interviews with thought leaders and experts.

Epidemiology: Incident cases and diagnosed prevalent cases of stages I-IV disease.

Population segments in market forecast: Adjuvant intermediate- and high-risk, metastatic (stage IV) first-line and second-line (after failure of first-line treatment in stage IV).

Emerging therapies: Phase II: 16 drugs; Phase III: 8 drugs. Coverage of 1 select Phase I product.

Market forecast features: Using a proprietary patient-flow model incorporating survival and progression from early to late stages, we forecast drug-treatable population sizes for clinically meaningful patient segments through 2017.

Alternative market scenarios: (1) combinations of targeted therapies are shown to be better than monotherapy; (2) multikinase inhibitors fail in the adjuvant setting; (3) multiple immunotherapies launch in the adjuvant setting.